The Science Behind PRV

A nano-engineered drug delivery platform — 100% locally concentrated, validated across four clinical trials

Our Technology

The PRV Platform: Six Core Advantages

The PRV Platform delivers potent therapies locally across multiple dosage forms — patches, injectables, hydrogels, and foam.

🎯

Locoregional Delivery

Penetrates tumor tissue and reaches regional lymph nodes with no systemic effects. Delivers highly concentrated therapy precisely where it is needed without damaging surrounding healthy tissue.

⚡

Enhanced Efficacy

Increased cancer cell uptake and local drug retention with nanotechnology and polymeric matrix protecting API from premature activation/degradation; enables delivery of highly concentrated APIs; supports immunomodulation and immunogenesis driving superior outcomes.

🛡️

Improved Safety

Excellent safety profile by avoiding healthy tissue and systemic circulation in blood; fully biodegradable and biocompatible.

🔧

Versatile Across Modalities

Capable of encapsulating small molecules, proteins, mAbs and combination therapies; delivery across various form factors, including patches, injectables, hydrogels, orals, foam/paste, enabling substantial expansion opportunities.

✅

Validated Technology

Safety and efficacy validated across four clinical trials; demonstrated breakthrough 95.5%(1) pCR rate and 100% surgery elimination in Phase 2/3 HGD/CIS.

🔒

Multi-Layered IP Protection

(1) Based on tumors treated
The Challenge

Localized Disease Needs Localized Treatment

Oral carcinoma in situ and high-grade dysplasia are localized diseases. They are currently treated with surgery which can be a devastating procedure that affects speech, swallowing, appearance, and quality of life.

Systemic chemotherapy is not an option, as it exposes the entire body to cytotoxic drug despite the disease being confined to a small tissue site. Patients face an urgent need for a non-surgical alternative, as there are no therapeutics approved to treat these diseases.

Privo's PRV Platform was engineered to solve this problem by delivering highly concentrated drug precisely where it is needed. By delivering and maintaining high doses of drug directly to the target site, it offers a tissue-sparing alternative to surgical resection. This approach limits systemic exposure and preserves the patients' quality of life.

259×

Higher cisplatin concentration in the tumor compared to intravenous administration

182×

Lower drug concentration in the blood vs. IV cisplatin — protecting healthy tissue

80×

Higher lymph node concentration vs. IV cisplatin — reaching regional disease

How It Works

Privo's Platform Amplifies a Well Understood & Validated Cisplatin MoA

Well Understood & Validated MoA

Cisplatin is a well-understood, platinum-based alkylating-like agent that kills cancer cells, particularly those dividing rapidly, by forming covalent platinum-DNA adducts (mainly intra-strand crosslinks).

These adducts distort the DNA structure, inhibiting replication and transcription, which activates DNA damage response pathways (i.e. p53) and triggers apoptosis.

Cisplatin mechanism — DNA adduct formation and apoptosis
+
Highly Concentrated & Localized Delivery Drives Differentiated MoA
  • 1
    Therapy-induced ER stress leads to exposure of calreticulin on the plasma membrane, triggering an “eat-me” signal
  • 2
    Induction of apoptosis leads to release of extracellular ATP, which acts as a chemoattractant, recruiting DCs to the tumor site and inducing DC maturation
  • 3
    During secondary necrosis, cell membrane becomes permeable, releasing HMGB-1, and enhancing downstream activation of T cells, such as CD4 and CD8
Immunomodulatory cascade — calreticulin, ATP, HMGB-1
Precision Local and High Concentration Delivery Enhances Both the Standard MoA and the Immunomodulatory Effects for Superior Clinical Outcomes